Aligos Therapeutics unveiled clinical progress across two therapeutic programs at the Conference on Retroviruses and Opportunistic Infections (CROI) held in Denver. The company presented Phase 1 monotherapy data for pevifoscorvir sodium, a potential first-in-class and best-in-class capsid assembly modulator (CAM-E) designed to treat chronic hepatitis B virus infection. The data demonstrated robust viral suppression, supporting the compound's advancement in clinical development.
In a separate presentation, Aligos disclosed pharmacokinetic findings for ALG-097558, a pan-coronavirus protease inhibitor, in patient populations with renal and hepatic impairment. The pharmacokinetic analysis provides critical dosing information relevant to treating immunocompromised patients and those with organ dysfunction, expanding the potential applicability of the antiviral candidate.
These presentations represent key clinical milestones for Aligos as it pursues development of treatments for serious viral infections affecting hepatitis B and coronavirus-infected populations. The data from both programs will inform the company's continued development strategy and potential regulatory pathways.